5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction

This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effects of 5-alpha-reductase inhibitors (5ARIs) for treating lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO). © 2015 The Cochrane Collaboration.

Autores:
Tipo de recurso:
Fecha de publicación:
2015
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/23701
Acceso en línea:
https://doi.org/10.1002/14651858.CD011928
https://repository.urosario.edu.co/handle/10336/23701
Palabra clave:
Dutasteride
Finasteride
Steroid 5alpha reductase inhibitor
Article
Benign prostatic obstruction
Clinical protocol
Disease association
Disease severity
Drug effect
Human
International prostate symptom score
Lower urinary tract symptom
Outcome assessment
Priority journal
Prostate disease
Quality of life
Systematic review
Urine retention
Urogenital tract disease assessment
Rights
License
Abierto (Texto Completo)
id EDOCUR2_703935964b6c8c145b980f496a9376b7
oai_identifier_str oai:repository.urosario.edu.co:10336/23701
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
spelling 9f010be1-d9d7-44bb-a7bc-ee07ca255ea5-17d237125-3912-44c1-8e64-032c5f8009cc-1b475d2c7-f841-4565-9ad7-559a320ca34e-12020-05-26T00:04:38Z2020-05-26T00:04:38Z2015This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effects of 5-alpha-reductase inhibitors (5ARIs) for treating lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO). © 2015 The Cochrane Collaboration.application/pdfhttps://doi.org/10.1002/14651858.CD0119281469493Xhttps://repository.urosario.edu.co/handle/10336/23701engJohn Wiley and Sons LtdNo. 11Cochrane Database of Systematic ReviewsVol. 2015Cochrane Database of Systematic Reviews, ISSN:1469493X, Vol.2015, No.11 (2015)https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041748285&doi=10.1002%2f14651858.CD011928&partnerID=40&md5=c8b19146507d0ecf36cf8c96f7f941e1Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURDutasterideFinasterideSteroid 5alpha reductase inhibitorArticleBenign prostatic obstructionClinical protocolDisease associationDisease severityDrug effectHumanInternational prostate symptom scoreLower urinary tract symptomOutcome assessmentPriority journalProstate diseaseQuality of lifeSystematic reviewUrine retentionUrogenital tract disease assessment5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstructionarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501García?Perdomo, Herney ALopez, Hugo ETacklind, James10336/23701oai:repository.urosario.edu.co:10336/237012021-06-03 00:52:05.845https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction
title 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction
spellingShingle 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction
Dutasteride
Finasteride
Steroid 5alpha reductase inhibitor
Article
Benign prostatic obstruction
Clinical protocol
Disease association
Disease severity
Drug effect
Human
International prostate symptom score
Lower urinary tract symptom
Outcome assessment
Priority journal
Prostate disease
Quality of life
Systematic review
Urine retention
Urogenital tract disease assessment
title_short 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction
title_full 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction
title_fullStr 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction
title_full_unstemmed 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction
title_sort 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction
dc.subject.keyword.spa.fl_str_mv Dutasteride
Finasteride
Steroid 5alpha reductase inhibitor
Article
Benign prostatic obstruction
Clinical protocol
Disease association
Disease severity
Drug effect
Human
International prostate symptom score
Lower urinary tract symptom
Outcome assessment
Priority journal
Prostate disease
Quality of life
Systematic review
Urine retention
Urogenital tract disease assessment
topic Dutasteride
Finasteride
Steroid 5alpha reductase inhibitor
Article
Benign prostatic obstruction
Clinical protocol
Disease association
Disease severity
Drug effect
Human
International prostate symptom score
Lower urinary tract symptom
Outcome assessment
Priority journal
Prostate disease
Quality of life
Systematic review
Urine retention
Urogenital tract disease assessment
description This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effects of 5-alpha-reductase inhibitors (5ARIs) for treating lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO). © 2015 The Cochrane Collaboration.
publishDate 2015
dc.date.created.spa.fl_str_mv 2015
dc.date.accessioned.none.fl_str_mv 2020-05-26T00:04:38Z
dc.date.available.none.fl_str_mv 2020-05-26T00:04:38Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1002/14651858.CD011928
dc.identifier.issn.none.fl_str_mv 1469493X
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/23701
url https://doi.org/10.1002/14651858.CD011928
https://repository.urosario.edu.co/handle/10336/23701
identifier_str_mv 1469493X
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationIssue.none.fl_str_mv No. 11
dc.relation.citationTitle.none.fl_str_mv Cochrane Database of Systematic Reviews
dc.relation.citationVolume.none.fl_str_mv Vol. 2015
dc.relation.ispartof.spa.fl_str_mv Cochrane Database of Systematic Reviews, ISSN:1469493X, Vol.2015, No.11 (2015)
dc.relation.uri.spa.fl_str_mv https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041748285&doi=10.1002%2f14651858.CD011928&partnerID=40&md5=c8b19146507d0ecf36cf8c96f7f941e1
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.spa.fl_str_mv Abierto (Texto Completo)
rights_invalid_str_mv Abierto (Texto Completo)
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv John Wiley and Sons Ltd
institution Universidad del Rosario
dc.source.instname.spa.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1814167599296020480

Publicaciones similares